Ambu A/S (AMBBY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ambu A/S (AMBBY) trades at $9.70 with AI Score 47/100 (Grade C). Ambu A/S is a Danish medical device company specializing in single-use endoscopes and other medical equipment. Market cap: $2.58B, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for AMBBY: AMBBY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AMBBY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
AMBBY: the 1 perspectives are evenly split.
How is this calculated? →Ambu A/S (AMBBY) Healthcare & Pipeline Overview
Ambu A/S, a Danish medical device innovator, focuses on single-use endoscopes and related medical solutions. With a global presence, the company addresses visualization, anesthesia, and patient monitoring needs, differentiating itself through its emphasis on disposable devices within the competitive medical device landscape, marked by companies like AMFPF and BUHPF.
What Is the Investment Thesis for AMBBY?
Ambu A/S presents a compelling investment case based on its innovative single-use endoscope technology and expanding market presence. With a market capitalization of $2.58B and a P/E ratio of 36.7, the company demonstrates solid financial standing. Key value drivers include the increasing adoption of single-use endoscopes to reduce infection risks and improve workflow efficiency in hospitals. Growth catalysts include expanding product lines and geographic reach, particularly in North America and Asia. However, potential risks include competition from established medical device manufacturers and the need for continuous innovation to maintain market leadership. The company's gross margin of 55.9% and profit margin of 8.9% indicate healthy profitability, while its beta of 1.40 suggests higher volatility compared to the market.
Based on FMP financials and quantitative analysis
AMBBY Key Highlights
- Market capitalization of $2.58B reflects investor confidence in Ambu's growth potential.
- P/E ratio of 36.7 indicates a premium valuation, reflecting expectations of future earnings growth.
- Gross margin of 55.9% demonstrates efficient cost management and strong pricing power.
- Profit margin of 8.9% showcases the company's ability to convert revenue into profit.
- Dividend yield of 0.57% provides a modest income stream for investors.
Who Are AMBBY's Competitors?
AMBBY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMFPF Amplifon S.p.A. | $11.21 | +0.00% | $2.47B | 38 |
| BUHPF Bumrungrad Hospital Public Company Limited | $5.45 | +0.00% | $4.33B | 47 |
| CAMRF Camurus AB (publ) | $60.00 | -1.66% | $3.60B | 63 |
| CZMWF Carl Zeiss Meditec AG | $30.00 | +0.00% | $2.63B | 49 |
| CZMWY Carl Zeiss Meditec AG | $32.76 | +3.56% | $2.87B | 51 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AMBBY's Key Strengths?
- Innovative single-use endoscope technology
- Strong brand reputation
- Established distribution network
- Focus on infection control
What Are AMBBY's Weaknesses?
- Reliance on single-use products
- Limited presence in some geographic markets
- Higher cost compared to reusable endoscopes
- Dependence on regulatory approvals
What Could Drive AMBBY Stock Higher?
- Increasing adoption of single-use endoscopes in hospitals and clinics due to infection control concerns.
- Potential new product launches in the single-use endoscopy market within the next 12-18 months.
- Expansion into new geographic markets, particularly in Asia-Pacific, driving revenue growth.
- Strategic partnerships or acquisitions to expand product portfolio and market access by 2027.
- Growing awareness of the benefits of single-use devices in terms of cost-effectiveness and workflow efficiency.
What Are the Key Risks for AMBBY?
- Rich valuation — a P/E of 36.7 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Competition from established medical device manufacturers with greater resources and market share.
- Pricing pressure from healthcare providers and insurance companies may impact profitability.
- Technological obsolescence could render existing products less competitive.
- Changes in regulatory requirements could increase compliance costs and delay product approvals.
- Currency fluctuations may negatively impact revenue and earnings.
What Are the Growth Opportunities for AMBBY?
- Expansion in the U.S. Market: Ambu has a significant opportunity to expand its presence in the U.S. market, driven by the increasing adoption of single-use endoscopes in hospitals and ambulatory surgery centers. The U.S. medical device market is the largest in the world, with a growing emphasis on infection control and cost-effectiveness. Ambu's single-use endoscopes offer a compelling value proposition in this context. The company can leverage its existing sales infrastructure and distribution network to penetrate new accounts and expand its market share. This expansion is expected to contribute significantly to revenue growth over the next 3-5 years.
- Product Innovation and Expansion: Ambu can drive growth through continuous product innovation and expansion of its single-use endoscope portfolio. The company has a strong track record of developing and launching new products that address unmet clinical needs. By investing in R&D and collaborating with healthcare professionals, Ambu can develop innovative solutions for various medical specialties, including pulmonology, urology, and gastroenterology. This product expansion will enable Ambu to capture a larger share of the endoscopy market and drive revenue growth. New product launches are anticipated within the next 2-3 years.
- Geographic Expansion in Asia-Pacific: The Asia-Pacific region represents a significant growth opportunity for Ambu, driven by the increasing healthcare expenditure and rising demand for advanced medical technologies. Countries such as China, India, and Japan are experiencing rapid economic growth and are investing heavily in healthcare infrastructure. Ambu can leverage its existing presence in the region and expand its sales and marketing efforts to capture a larger share of the market. This geographic expansion is expected to contribute significantly to revenue growth over the next 3-5 years.
- Strategic Partnerships and Acquisitions: Ambu can accelerate its growth through strategic partnerships and acquisitions. The company can partner with other medical device manufacturers, distributors, and healthcare providers to expand its product portfolio, geographic reach, and market access. Acquisitions can also provide Ambu with access to new technologies, markets, and customer segments. These strategic initiatives can enhance Ambu's competitive position and drive long-term growth. Potential partnerships and acquisitions are being evaluated on an ongoing basis.
- Increased Adoption of Single-Use Endoscopes: The increasing awareness of infection control and the need for efficient workflow in hospitals are driving the adoption of single-use endoscopes. Ambu is well-positioned to benefit from this trend, as its single-use endoscopes offer a compelling value proposition in terms of safety, convenience, and cost-effectiveness. The company can leverage its marketing and sales efforts to educate healthcare professionals about the benefits of single-use endoscopes and drive adoption. This increased adoption is expected to contribute significantly to revenue growth over the next 3-5 years.
What Opportunities Does AMBBY Have?
- Expansion in the U.S. market
- Product innovation and expansion
- Geographic expansion in Asia-Pacific
- Strategic partnerships and acquisitions
What Threats Does AMBBY Face?
- Competition from established medical device manufacturers
- Pricing pressure from healthcare providers
- Technological obsolescence
- Changes in regulatory requirements
What Are AMBBY's Competitive Advantages?
- Proprietary single-use endoscope technology.
- Strong brand reputation for innovation and quality.
- Established distribution network and customer relationships.
- Focus on infection control and workflow efficiency.
What Does AMBBY Do?
Founded in 1937 and headquartered in Ballerup, Denmark, Ambu A/S has evolved into a key player in the medical device industry. Initially focused on developing and marketing resuscitation equipment, Ambu gained recognition for inventing the first self-inflating resuscitator bag. Over the decades, the company expanded its product portfolio to include a wide array of medical devices, with a strategic emphasis on single-use endoscopes. These endoscopes are used in various medical procedures, including bronchoscopy, cystoscopy, and rhinolaryngoscopy. Ambu's product offerings also encompass visualization, anesthesia, and patient monitoring and diagnostics. The company serves hospitals, clinics, and rescue services worldwide. Ambu's global reach extends across North America, Europe, and Asia-Pacific, with a direct sales force and a network of distributors. The company's focus on innovation and single-use devices positions it uniquely within the competitive medical device market, challenging traditional reusable equipment models.
What Products and Services Does AMBBY Offer?
- Develops single-use endoscopes for various medical procedures.
- Produces visualization devices for bronchoscopy, cystoscopy, and rhinolaryngoscopy.
- Offers anesthesia products, including face masks and resuscitators.
- Provides patient monitoring and diagnostic equipment.
- Manufactures neurology products, such as EEG and EMG electrodes.
- Creates cardiology products, including ECG electrodes.
- Supplies airway management and anaesthesia products.
How Does AMBBY Make Money?
- Develops, manufactures, and sells medical devices.
- Focuses on single-use endoscopes and related products.
- Distributes products through a direct sales force and a network of distributors.
- Generates revenue from product sales to hospitals, clinics, and rescue services.
What Industry Does AMBBY Operate In?
Ambu A/S operates within the global medical device industry, a market characterized by continuous innovation and increasing demand for advanced healthcare solutions. The industry is driven by factors such as an aging population, rising healthcare expenditure, and technological advancements. The single-use endoscope market, in particular, is experiencing rapid growth due to concerns about infection control and the need for efficient workflow in hospitals. Ambu competes with established medical device manufacturers such as AMFPF and BUHPF, as well as smaller players specializing in endoscopy and related products. The company's focus on single-use devices positions it favorably in this evolving landscape.
Who Are AMBBY's Key Customers?
- Hospitals
- Clinics
- Rescue services
- Ambulatory surgery centers
Ambu A/S Financial Trajectory
Ambu A/S (AMBBY) reported $1.60B in revenue for Q1 2026, reflecting 2.6% growth compared to the prior quarter. The company recorded net income of $123.0M, with diluted EPS of $0.46. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company.
Company Profile
Ambu A/S operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Ballerup, DK. The company is led by CEO Britt Meelby Jensen. AMBBY has traded publicly since 2021.
How Ambu A/S Is Valued
Ambu A/S carries a market capitalization of $2.58B, placing it in the mid-cap category. Relative to its peer group, AMBBY's quantitative score of 47/100 is roughly in line with the peer average of 50/100.
ROE 8%Key Financial Metrics
Return on equity for Ambu A/S stands at 7.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.3%, showing how much profit it generates from its asset base. AMBBY trades at a trailing price-to-earnings ratio of 36.69, above the Healthcare sector average of ~23x. Its free cash flow yield is 3.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.92 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 5/9Financial Health
Ambu A/S's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 5.93 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Ambu A/S revenue of about $6.46B for fiscal 2026, with EPS near $0.00. The estimate reflects 8 contributing analysts.
AMBBY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Insider buying has increased recently, indicating confidence from leadership in Ambu's future prospects.
- Community sentiment has shifted positively, with discussions highlighting Ambu's innovative product pipeline and potential market expansion.
- Recent regulatory approvals for new medical devices have bolstered optimism about Ambu's growth trajectory.
- Analysts are noting a favorable shift in healthcare spending, which could benefit Ambu's sales in the near term.
Bear Case
- Concerns about supply chain disruptions have surfaced, potentially impacting Ambu's ability to meet demand.
- Negative sentiment in forums reflects worries about competition in the medical device sector, which could erode market share.
- Recent earnings reports have not met investor expectations, leading to skepticism about Ambu's short-term performance.
- Market perception remains cautious due to broader economic uncertainties affecting healthcare budgets.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.60B | $123M | $0.46 |
| Q4 2025 | $1.56B | $118M | $0.44 |
| Q2 2025 | $1.51B | $123M | $0.46 |
Based on FMP financials and quantitative analysis
AMBBY Latest News
-
Top European Growth Companies With High Insider Ownership In May 2026
Yahoo! Finance: AMBBY News · May 26, 2026
AMBBY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AMBBY.
Price Targets
Wall Street price target analysis for AMBBY.
AMBBY MoonshotScore
What does this score mean?
The MoonshotScore rates AMBBY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Britt Meelby Jensen
CEO
Britt Meelby Jensen serves as the CEO of Ambu A/S, leading a global workforce of 5000 employees. Her career spans various leadership roles within the healthcare and pharmaceutical industries. Prior to joining Ambu, she held executive positions at companies such as Novo Nordisk and ALK-Abelló, where she focused on commercial strategy, market access, and business development. Jensen holds a Master's degree in Economics and Business Administration from Copenhagen Business School.
Track Record: Since assuming the role of CEO, Britt Meelby Jensen has focused on driving growth through innovation, geographic expansion, and strategic partnerships. Under her leadership, Ambu has strengthened its position in the single-use endoscope market and expanded its product portfolio. She has also overseen the company's expansion into new markets, particularly in North America and Asia. Key milestones include the launch of several new single-use endoscope products and the acquisition of a complementary medical device company.
Ambu A/S ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that are traded on U.S. stock exchanges. AMBBY functions as a Level 1 ADR, meaning it trades over-the-counter (OTC) without the same stringent SEC reporting requirements as listed companies. This allows U.S. investors to invest in Ambu A/S without directly dealing with foreign stock exchanges.
- Home Market Ticker: Nasdaq Copenhagen, Denmark
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: AMBB
AMBBY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited financial disclosure and may not meet minimum listing requirements of major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the potential for less transparency, lower liquidity, and greater price volatility compared to exchange-listed securities. This tier is distinct from the higher OTCQX and OTCQB tiers, which have more stringent listing standards.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Lower trading volume and liquidity
- Wider bid-ask spreads
- Greater price volatility
- Potential for fraud or manipulation
- Verify the company's registration and regulatory filings.
- Review the company's financial statements, if available.
- Assess the company's management team and track record.
- Research the company's industry and competitive landscape.
- Evaluate the company's business model and growth prospects.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Established operating history (founded in 1937).
- Global presence and customer base.
- Focus on innovation and single-use medical devices.
- Presence of a recognized CEO (Britt Meelby Jensen).
- ADR listing, even at Level 1, indicates some level of compliance.
What Investors Ask About Ambu A/S (AMBBY) — Healthcare
What does Ambu A/S do?
Ambu A/S is a medical device company specializing in the development, production, and sale of single-use endoscopes and other medical equipment. The company provides healthcare solutions in the fields of visualization, anesthesia, and patient monitoring and diagnostics. Its primary focus is on single-use endoscopes, which are used in various medical procedures, including bronchoscopy, cystoscopy, and rhinolaryngoscopy. Ambu's products are sold to hospitals, clinics, and rescue services worldwide.
What do analysts say about AMBBY stock?
Analyst coverage of AMBBY is limited due to its OTC listing. However, the company's focus on single-use endoscopes and its growth potential in the medical device market are generally viewed positively. Key valuation metrics include the company's P/E ratio of 36.7 and its market capitalization of $2.58B. Growth considerations include the increasing adoption of single-use devices and the company's expansion into new markets. Investors should conduct their own research and consider their individual risk tolerance before investing in AMBBY.
What are the main risks for AMBBY?
The main risks for AMBBY include competition from established medical device manufacturers, pricing pressure from healthcare providers, technological obsolescence, changes in regulatory requirements, and currency fluctuations. As an OTC-listed stock, AMBBY also faces risks related to limited financial disclosure, lower trading volume, and greater price volatility. Investors should carefully consider these risks before investing in AMBBY.
How does Ambu A/S manage patent expiration risks?
As a medical device company, Ambu A/S faces the risk of patent expirations on its key products. To mitigate this risk, Ambu invests in continuous research and development to develop new and innovative products. The company also employs lifecycle management strategies to extend the commercial life of its existing products, such as developing new formulations or indications. Ambu also actively monitors the competitive landscape and prepares for the entry of biosimilar or generic products upon patent expiration.
What revenue streams does Ambu A/S have in healthcare?
Ambu A/S generates revenue from the sale of its medical devices to hospitals, clinics, and rescue services worldwide. The company's revenue streams are diversified across various product lines, including single-use endoscopes, anesthesia products, and patient monitoring equipment. Geographically, Ambu generates revenue from North America, Europe, and Asia-Pacific. The company's revenue is also diversified across various medical specialties, including pulmonology, urology, and gastroenterology. The single-use endoscope segment is a significant contributor to Ambu's overall revenue.
What are the key factors to evaluate for AMBBY?
Ambu A/S (AMBBY) holds an AI score of 47/100 (low). P/E: 36.7x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does AMBBY data refresh on this page?
AMBBY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven AMBBY's recent stock price performance?
Ambu A/S (AMBBY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative single-use endoscope technology. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC data may be less reliable than exchange-listed data.
- Analyst coverage may be limited due to OTC listing.